Why Suprathel is Used for Deeper Burns Compared to Biobrane
Suprathel demonstrates superior outcomes in deeper partial-thickness burns with shorter hospital stays, lower rates of escharectomy and grafting, and reduced need for long-term reintervention compared to Biobrane.
Evidence-Based Rationale
The preference for Suprathel over Biobrane in deeper partial-thickness burns is supported by direct comparative research showing clinically meaningful differences in patient outcomes:
Key Performance Differences
Hospital Stay and Acute Management: A large pediatric study of 378 burn patients directly comparing these materials found that Suprathel-treated patients had a median hospital stay of 4 days versus 9 days for Biobrane 1. More critically, the escharectomy and grafting rate during acute management was significantly lower with Suprathel (21.1%) compared to Biobrane (32.1%) 1. This suggests Suprathel better preserves viable tissue in deeper burns, preventing wound progression that would otherwise require surgical intervention.
Long-Term Outcomes: The same study demonstrated that Suprathel had an 18.5% long-term reintervention rate compared to 26.2% for Biobrane 1. This reduction in secondary procedures directly impacts both morbidity and quality of life by minimizing additional surgeries, anesthesia exposure, and scar revision needs.
Clinical Application in Deeper Burns
Wound Depth Considerations: While both materials work well for superficial partial-thickness burns, the distinction becomes critical in deeper partial-thickness injuries. Suprathel's effectiveness after tangential excision of burn eschar in "more superficial deep partial-thickness burns" provides a reliable alternative to autologous skin grafting 2. This is particularly valuable because it avoids donor site morbidity while achieving satisfactory healing times.
Material Adherence and Wound Progression: A critical limitation of both materials is premature detachment, which correlates with burn depth progression 3. However, the lower conversion rate to grafting with Suprathel suggests it maintains better adherence or provides superior wound bed preparation in deeper injuries.
Comparative Performance Data
One head-to-head study showed Biobrane had slightly faster healing (1.8 days shorter) in superficial burns 4, but this advantage disappears in deeper burns where the risk of wound conversion becomes the primary concern. The study found no significant differences in scar quality (Vancouver Scar Scale) or skin elasticity (Cutometer parameters) at 8 months 4, suggesting equivalent long-term cosmetic outcomes when both materials successfully adhere.
Clinical Decision Algorithm
For superficial partial-thickness burns (intact dermis, minimal depth):
- Either material is acceptable
- Consider Biobrane for slightly faster healing
- Cost may be a deciding factor
For deeper partial-thickness burns (approaching deep dermal involvement):
- Prefer Suprathel due to:
- Lower conversion to grafting (21.1% vs 32.1%)
- Shorter hospital stays (4 vs 9 days median)
- Reduced long-term reintervention needs (18.5% vs 26.2%)
High-risk locations for premature detachment (joints, hands, feet):
- Expect higher failure rates with both materials 3
- Consider earlier surgical intervention if detachment occurs
- Younger children have higher detachment risk 3
Important Caveats
Wound Assessment Accuracy: The critical distinction is accurate initial burn depth assessment. Deeper partial-thickness burns that appear superficial initially may progress, and Suprathel's lower conversion rate suggests it better accommodates this progression.
Cost Considerations: While the 2011 study noted cost as an important selection criterion 4, the 2024 data showing reduced hospital stays and surgical interventions with Suprathel likely offset higher material costs through decreased overall resource utilization 1.
Guideline Context: The available burn care guidelines 5 mention Biobrane for physiological closure in early presentation with noninfected areas but do not specifically address comparative effectiveness with Suprathel, as these guidelines predate the comparative research.